Clinical Trial

Life Sciences Community Advances Toward Next Phase of Innovation at Veeva R&D and Quality Summit

AbbVie, Astellas, Eikon, Merck, Moderna, Roche, and more share new ideas to advance drug development PLEASANTON, Calif., Aug. 13, 2024…

5 months ago

Acclinate Ranks No. 539 on the 2024 Inc. 5000 List

NEW YORK, Aug. 13, 2024 /PRNewswire/ -- Inc. magazine revealed today that Acclinate has ranked No. 539 on its 2024…

5 months ago

Leapcure Acquires Honeybee Trials: Expanding Patient Engagement and Research Site Solutions for Clinical Trials

Leapcure enhances clinical trials and affordable patient recruitment with strategic acquisition of Honeybee Trials.REDWOOD CITY, CA / ACCESSWIRE / August…

5 months ago

U.S. News & World Report Ranks John Theurer Cancer Center as the #1 Cancer Program in NJ and the Only Top 50 Cancer Program in the State

Regional Cancer Care Associates is pleased to announce the recognition of John Theurer Cancer Center as the #1 Cancer Program…

5 months ago

Phase 1b/2 “RAINIER” Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination with standard of care venetoclax and azacitidineCompany anticipates new data…

5 months ago

Jaguar Health Reports Second Quarter 2024 Financial Results

The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net…

5 months ago

NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024

CARMEL, Ind., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology…

5 months ago

Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization

The ISO 13485 certification is a validation of the Company’s robust quality systemBRAINTREE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) --…

5 months ago

COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results

                Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone…

5 months ago

Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of…

5 months ago